1. CMTM4 is a subunit of the IL-17 receptor and mediates autoimmune pathology
- Author
-
Daniela Knizkova, Michaela Pribikova, Helena Draberova, Tereza Semberova, Tijana Trivic, Alzbeta Synackova, Andrea Ujevic, Jana Stefanovic, Ales Drobek, Martina Huranova, Veronika Niederlova, Oksana Tsyklauri, Ales Neuwirth, Jolana Tureckova, Ondrej Stepanek, and Peter Draber
- Subjects
Mice ,Receptors, Interleukin-17 ,Encephalomyelitis, Autoimmune, Experimental ,MARVEL Domain-Containing Proteins ,Immunology ,Interleukin-17 ,Arthritis, Psoriatic ,Immunology and Allergy ,Humans ,Animals ,Psoriasis - Abstract
Interleukin-17A (IL-17A) is a key mediator of protective immunity to yeast and bacterial infections but also drives the pathogenesis of several autoimmune diseases, such as psoriasis or psoriatic arthritis. Here we show that the tetra-transmembrane protein CMTM4 is a subunit of the IL-17 receptor (IL-17R). CMTM4 constitutively associated with IL-17R subunit C to mediate its stability, glycosylation and plasma membrane localization. Both mouse and human cell lines deficient in CMTM4 were largely unresponsive to IL-17A, due to their inability to assemble the IL-17R signaling complex. Accordingly, CMTM4-deficient mice had a severe defect in the recruitment of immune cells following IL-17A administration and were largely resistant to experimental psoriasis, but not to experimental autoimmune encephalomyelitis. Collectively, our data identified CMTM4 as an essential component of IL-17R and a potential therapeutic target for treating IL-17-mediated autoimmune diseases.
- Published
- 2021